- Home
- CABA vs TRUE Comparison
CABA vs TRUE Comparison
Compare CABA & TRUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- TRUE
- Stock Information
- Founded
- CABA 2017
- TRUE 2005
- Country
- CABA United States
- TRUE United States
- Employees
- CABA N/A
- TRUE N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- TRUE Computer Software: Programming Data Processing
- Sector
- CABA Health Care
- TRUE Technology
- Exchange
- CABA Nasdaq
- TRUE Nasdaq
- Market Cap
- CABA 149.3M
- TRUE 171.0M
- IPO Year
- CABA 2019
- TRUE 2014
- Fundamental
- Price
- CABA $1.71
- TRUE $1.98
- Analyst Decision
- CABA Strong Buy
- TRUE Buy
- Analyst Count
- CABA 7
- TRUE 5
- Target Price
- CABA $14.29
- TRUE $3.19
- AVG Volume (30 Days)
- CABA 1.3M
- TRUE 481.0K
- Earning Date
- CABA 08-07-2025
- TRUE 08-06-2025
- Dividend Yield
- CABA N/A
- TRUE N/A
- EPS Growth
- CABA N/A
- TRUE N/A
- EPS
- CABA N/A
- TRUE N/A
- Revenue
- CABA N/A
- TRUE $184,559,000.00
- Revenue This Year
- CABA N/A
- TRUE $7.54
- Revenue Next Year
- CABA N/A
- TRUE $11.02
- P/E Ratio
- CABA N/A
- TRUE N/A
- Revenue Growth
- CABA N/A
- TRUE 11.66
- 52 Week Low
- CABA $0.99
- TRUE $1.05
- 52 Week High
- CABA $6.26
- TRUE $4.62
- Technical
- Relative Strength Index (RSI)
- CABA 57.70
- TRUE 50.40
- Support Level
- CABA $1.26
- TRUE $1.88
- Resistance Level
- CABA $1.56
- TRUE $2.29
- Average True Range (ATR)
- CABA 0.12
- TRUE 0.18
- MACD
- CABA 0.00
- TRUE -0.01
- Stochastic Oscillator
- CABA 92.78
- TRUE 47.68
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About TRUE TrueCar Inc.
TrueCar Inc is a data-driven online platform operating on common technology infrastructure, powered by proprietary data and analytics. It also customizes and operates its platform for affinity group marketing partners, including financial institutions like PenFed and American Express; membership-based organizations like Consumer Reports, AARP, Sam's Club, and AAA; and employee buying programs for large enterprises such as IBM and Walmart. The Company has one operating segment, with three distinct service offerings: Dealer products and services, OEM incentives, and other.